Idorsia Ltd IDRSF
Set alert
4.95 USD -0.43 -7.99%
At close · Oct 30
4.40 Day range 4.40
3.82 52-week range 8.19
- YTD
- -5.71%
- 1 year
- +13.27%
- Open
- 4.40
- Prev close
- 5.38
- Mkt cap
- 1.34B
- Vol
- 250
- Avg vol
- 1.60K
- EPS
- -1.74
- P/E
- 0.00
More statistics
- Low
- 4.40
- High
- 4.40
- Earnings
- Oct 29, 2026
2Y chart
Events in this range
- Jul 30, 2025Earnings: -0.07603; estimate -0.25208; surprise 69.84%
- Oct 30, 2025Earnings: -0.34526; estimate -0.27621; surprise -25%
- Feb 26, 2026Earnings: -0.34058; estimate -0.24597; surprise -38.46%
- Apr 28, 2026Earnings: -0.17518; estimate -0.23148; surprise 24.32%
- Jul 30, 2026Earnings: -0.20412; estimate -0.24123; surprise 15.38%
- Oct 29, 2026Earnings: —; estimate -0.33437; surprise —%
Signals (55)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| RSI: Overbought | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| RSI: Overbought | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 6, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| RSI: Oversold | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 7 months ago |
| RSI: Overbought | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 9, 2026 | 8 months ago |
| RSI: Overbought | Feb 9, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 7, 2026 | 9 months ago |
| RSI: Overbought | Dec 31, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| RSI: Oversold | Nov 6, 2025 | 11 months ago |
| SMA: Bearish | Nov 5, 2025 | 12 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 23, 2025 | 1 year ago |
| RSI: Overbought | Sep 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 6, 2025 | 1 year ago |
| SMA: Bullish | May 9, 2025 | 1 year ago |
| RSI: Overbought | May 9, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Feb 27, 2025 | 1 year ago |
| RSI: Overbought | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 30, 2025 | 1 year ago |
| RSI: Oversold | Jan 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| RSI: Oversold | Dec 26, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 24, 2024 | 1 year ago |
| RSI: Overbought | Dec 12, 2024 | 1 year ago |
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate -0.33437.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | -0.33437 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.24123 | -0.20412 | +0.04 | +15.38% |
| Apr 28, 2026 | Mar 31, 2026 | -0.23148 | -0.17518 | +0.06 | +24.32% |
| Feb 26, 2026 | Dec 31, 2025 | -0.24597 | -0.34058 | -0.09 | -38.46% |
| Oct 30, 2025 | Sep 30, 2025 | -0.27621 | -0.34526 | -0.07 | -25.00% |
| Jul 30, 2025 | Jun 30, 2025 | -0.25208 | -0.07603 | +0.18 | +69.84% |
News
- Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript
- Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
- Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
- New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
- Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
- Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
- Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
- Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
- Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
- Idorsia announces the nomination of three candidates for election to the Board of Directors
Your note
Sign in to keep a note on IDRSF — it syncs with the Stock Master app.